Collaboration expanded to explore synthetically feasible chemical space
Enamine REAL database of synthetic compounds accessible via UCSF’s online ZINC platform.
Enamine, a chemical research organization and producer of novel building blocks and screening libraries, has expanded its collaboration on ZINC, a comprehensive online database of purchasable compounds curated by the Irwin and Shoichet laboratories in the Department of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF). Via ZINC, Enamine will provide researchers at UCSF and the global drug-discovery community with access to the company’s REAL database, a unique database of more than 300 million novel synthetically feasible chemical structures as an efficient source of potential new compounds for a breadth of drug discovery projects.
The REAL database is the most significant contribution to currently purchasable chemical space, accounting for over 90% of all structures in ZINC. The compounds are conveniently selected in ZINC and then synthesized by Enamine in a single step from its building block stock, ensuring quick delivery and a high success rate.
Michael Bossert, Head of Strategic Alliances at Enamine said: “The number of compounds that Enamine can quickly access with its stock of 150,000 building blocks is astonishing. ZINC is a powerful platform that can efficiently support our endeavors to further expand our chemical space coverage to the global drug discovery community. We are pleased to see the researchers at UCSF benefitting from the diversity and novelty of our structures in the REAL compound arrays.”
John Irwin, Adjunct Professor at the UCSF School of Pharmacy and curator of ZINC agreed: “As we strive to bridge the gap between chemoinformatics and biology, the importance of working within a purchasable chemical space cannot be underestimated. We are pleased to continue our collaboration with Enamine in exploring ways to provide novel chemical compounds, designed and synthesized specifically for each research project, to the global biomedical community.”
Most compounds from the REAL database have already been successfully uploaded to ZINC. Over the last year, 92% of the more than 250 compounds ordered from Enamine have been delivered successfully to UCSF.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance